170 related articles for article (PubMed ID: 37743344)
21. Promising response to vemurafenib and cobimetinib treatment for BRAF V600E mutated craniopharyngioma: a case report and literature review.
Yu N; Raslan OA; Lee HS; Theeler BJ; Raafat TA; Fragoso R; Shahlaie K; Aboud O
CNS Oncol; 2024 Jan; 13(1):CNS106. PubMed ID: 38348829
[TBL] [Abstract][Full Text] [Related]
22. Pathological and Prognostic Characterization of Craniopharyngioma Based on the Expression of TrkA, β-Catenin, Cell Cycle Markers, and BRAF V600E Mutation.
Xu C; Ge S; Cheng J; Gao H; Zhang F; Han A
Front Endocrinol (Lausanne); 2022; 13():859381. PubMed ID: 35707464
[TBL] [Abstract][Full Text] [Related]
23. The Medical Therapy of Craniopharyngiomas: The Way Ahead.
Alexandraki KI; Kaltsas GA; Karavitaki N; Grossman AB
J Clin Endocrinol Metab; 2019 Dec; 104(12):5751-5764. PubMed ID: 31369091
[TBL] [Abstract][Full Text] [Related]
24. A Clinical Rule for Preoperative Prediction of BRAF Mutation Status in Craniopharyngiomas.
Fujio S; Juratli TA; Arita K; Hirano H; Nagano Y; Takajo T; Yoshimoto K; Bihun IV; Kaplan AB; Nayyar N; Fink AL; Bertalan MS; Tummala SS; Curry WT; Jones PS; Martinez-Lage M; Cahill DP; Barker FG; Brastianos PK
Neurosurgery; 2019 Aug; 85(2):204-210. PubMed ID: 30481321
[TBL] [Abstract][Full Text] [Related]
25. Craniopharyngiomas.
Hamblin R; Tsermoulas G; Karavitaki N
Presse Med; 2021 Dec; 50(4):104078. PubMed ID: 34688870
[TBL] [Abstract][Full Text] [Related]
26. Pathology and pathogenesis of craniopharyngiomas.
Larkin SJ; Ansorge O
Pituitary; 2013 Mar; 16(1):9-17. PubMed ID: 22886701
[TBL] [Abstract][Full Text] [Related]
27. Adamantinomatous and papillary craniopharyngiomas are characterized by distinct epigenomic as well as mutational and transcriptomic profiles.
Hölsken A; Sill M; Merkle J; Schweizer L; Buchfelder M; Flitsch J; Fahlbusch R; Metzler M; Kool M; Pfister SM; von Deimling A; Capper D; Jones DT; Buslei R
Acta Neuropathol Commun; 2016 Feb; 4():20. PubMed ID: 26927026
[TBL] [Abstract][Full Text] [Related]
28. Potential evolution of neurosurgical treatment paradigms for craniopharyngioma based on genomic and transcriptomic characteristics.
Robinson LC; Santagata S; Hankinson TC
Neurosurg Focus; 2016 Dec; 41(6):E3. PubMed ID: 27903126
[TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant B-RAF and MEK Inhibitor Targeted Therapy for Adult Papillary Craniopharyngiomas: A New Treatment Paradigm.
Calvanese F; Jacquesson T; Manet R; Vasiljevic A; Lasolle H; Ducray F; Raverot G; Jouanneau E
Front Endocrinol (Lausanne); 2022; 13():882381. PubMed ID: 35757402
[TBL] [Abstract][Full Text] [Related]
30. Biological Behaviour of Craniopharyngiomas.
Martinez-Barbera JP; Andoniadou CL
Neuroendocrinology; 2020; 110(9-10):797-804. PubMed ID: 32126562
[TBL] [Abstract][Full Text] [Related]
31. [Etiology, Genetic Features and Clinical Presentations in Craniopharyngiomas].
Horiguchi K
No Shinkei Geka; 2023 Jul; 51(4):607-614. PubMed ID: 37491057
[TBL] [Abstract][Full Text] [Related]
32. Papillary craniopharyngioma in a 4-year-old girl with BRAF V600E mutation: a case report and review of the literature.
Borrill R; Cheesman E; Stivaros S; Kamaly-Asl ID; Gnanalingham K; Kilday JP
Childs Nerv Syst; 2019 Jan; 35(1):169-173. PubMed ID: 30069716
[TBL] [Abstract][Full Text] [Related]
33. ENDOCRINE TUMORS: BRAF V600E mutations in papillary craniopharyngioma.
Brastianos PK; Santagata S
Eur J Endocrinol; 2016 Apr; 174(4):R139-44. PubMed ID: 26563980
[TBL] [Abstract][Full Text] [Related]
34. Subtype-dependent difference of glucose transporter 1 and hexokinase II expression in craniopharyngioma: an immunohistochemical study.
Mukada N; Tosaka M; Matsumura N; Yamaguchi R; Aihara M; Isoda K; Higuchi T; Tsushima Y; Yokoo H; Yoshimoto Y
Sci Rep; 2021 Jan; 11(1):126. PubMed ID: 33420213
[TBL] [Abstract][Full Text] [Related]
35. Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy.
Brastianos PK; Shankar GM; Gill CM; Taylor-Weiner A; Nayyar N; Panka DJ; Sullivan RJ; Frederick DT; Abedalthagafi M; Jones PS; Dunn IF; Nahed BV; Romero JM; Louis DN; Getz G; Cahill DP; Santagata S; Curry WT; Barker FG
J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26498373
[TBL] [Abstract][Full Text] [Related]
36. Targeted Therapy in the Management of Modern Craniopharyngiomas.
Reyes M; Taghvaei M; Yu S; Sathe A; Collopy S; Prashant GN; Evans JJ; Karsy M
Front Biosci (Landmark Ed); 2022 Apr; 27(4):136. PubMed ID: 35468695
[TBL] [Abstract][Full Text] [Related]
37. Molecular defects in BRAF wild-type ameloblastomas and craniopharyngiomas-differences in mutation profiles in epithelial-derived oropharyngeal neoplasms.
Bartels S; Adisa A; Aladelusi T; Lemound J; Stucki-Koch A; Hussein S; Kreipe H; Hartmann C; Lehmann U; Hussein K
Virchows Arch; 2018 Jun; 472(6):1055-1059. PubMed ID: 29546640
[TBL] [Abstract][Full Text] [Related]
38. PROP1 and CTNNB1 expression in adamantinomatous craniopharyngiomas with or without β-catenin mutations.
Cani CM; Matushita H; Carvalho LR; Soares IC; Brito LP; Almeida MQ; Mendonça BB
Clinics (Sao Paulo); 2011; 66(11):1849-54. PubMed ID: 22086512
[TBL] [Abstract][Full Text] [Related]
39. Integrating Systemic Therapies into the Multimodality Therapy of Patients with Craniopharyngioma.
Gritsch D; Santagata S; Brastianos PK
Curr Treat Options Oncol; 2024 Feb; 25(2):261-273. PubMed ID: 38300480
[TBL] [Abstract][Full Text] [Related]
40. Can tissue biomarkers reliably predict the biological behavior of craniopharyngiomas? A comprehensive overview.
Prieto R; Pascual JM
Pituitary; 2018 Aug; 21(4):431-442. PubMed ID: 29700680
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
